- Home
- CASH vs KNSA Comparison
CASH vs KNSA Comparison
Compare CASH & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASH
- KNSA
- Stock Information
- Founded
- CASH 1954
- KNSA 2015
- Country
- CASH United States
- KNSA United Kingdom
- Employees
- CASH N/A
- KNSA N/A
- Industry
- CASH Major Banks
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- CASH Finance
- KNSA Health Care
- Exchange
- CASH Nasdaq
- KNSA Nasdaq
- Market Cap
- CASH 1.8B
- KNSA 2.1B
- IPO Year
- CASH N/A
- KNSA 2018
- Fundamental
- Price
- CASH $80.20
- KNSA $26.33
- Analyst Decision
- CASH Buy
- KNSA Strong Buy
- Analyst Count
- CASH 2
- KNSA 6
- Target Price
- CASH $91.00
- KNSA $39.33
- AVG Volume (30 Days)
- CASH 203.0K
- KNSA 994.2K
- Earning Date
- CASH 07-28-2025
- KNSA 07-29-2025
- Dividend Yield
- CASH 0.25%
- KNSA N/A
- EPS Growth
- CASH 10.71
- KNSA N/A
- EPS
- CASH 7.36
- KNSA N/A
- Revenue
- CASH $731,383,000.00
- KNSA $481,166,000.00
- Revenue This Year
- CASH $14.15
- KNSA $37.21
- Revenue Next Year
- CASH $5.99
- KNSA $5.32
- P/E Ratio
- CASH $10.90
- KNSA N/A
- Revenue Growth
- CASH 6.51
- KNSA 59.45
- 52 Week Low
- CASH $60.42
- KNSA $17.82
- 52 Week High
- CASH $86.00
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- CASH 48.87
- KNSA 38.53
- Support Level
- CASH $79.77
- KNSA $28.19
- Resistance Level
- CASH $84.75
- KNSA $29.58
- Average True Range (ATR)
- CASH 2.00
- KNSA 0.92
- MACD
- CASH -0.42
- KNSA -0.25
- Stochastic Oscillator
- CASH 8.50
- KNSA 1.81
About CASH Pathward Financial Inc.
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.